mTOR is a very promising pathway because it’s so central in growth, migration, and survival of bladder cancer cells, explained Donna Hansel, MD, PhD, chief, anatomic pathology, UC San Diego.
mTOR is a very promising pathway because it’s so central in growth, migration, and survival of bladder cancer cells, explained Donna Hansel, MD, PhD, chief, anatomic pathology, UC San Diego.
Transcript
Advanced bladder has limited therapeutic options when conventional therapy has failed. How does your lab approach the identification of targetable pathways for advanced bladder cancer?
So, my lab focuses primarily on the mammalian target of rapamycin, or mTOR, signaling pathway, and we know from The Cancer Genome Atlas (TCGA) data that was produced that a very large number of bladder cancers, advanced bladder cancers, have some sort of alteration that affects signaling through the mTOR pathway. Despite some initial trials looking at mTOR inhibition, we feel it’s a very promising pathway because it’s so central in growth, in migration, in survival of bladder cancer cells, that we’ve continued to study it.
What we’ve done is to focus on 2 aspects of mTOR signaling and to try and understand what happens downstream from it, because it’s very likely that if we understand more about the mTOR pathway, that includes both mTORC1 and mTORC2, we’ll be able to better define potentially more actionable targets that we could find downstream.
So, for example, focusing on mTORC2, which has been a big passion of my lab members, we have now identified approximately 50 downstream targets, novel targets, that do affect migration, and do affect invasion. In bladder cancer, it’s critical to understand that invasive pathway that leads to higher local stages, but it’s also important to understand how invasion and interaction with the endothelial cells then leads to metastasis. We’re finding more and more information studying mTORC2 that indeed there are a number of very unique regulators downstream that affect both of these pathways, and all of which are quite actionable.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More